Literature DB >> 8390289

High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal.

P Coursaget1, N Depril, M Chabaud, R Nandi, V Mayelo, P LeCann, B Yvonnet.   

Abstract

In hepatocellular carcinoma, mutation within the p53 gene occurs mainly at codon 249 and its frequency has been associated with exposure to aflatoxin. As Senegal is a country where liver cancer incidence is one of the highest in the world and where people are highly exposed to aflatoxin, we screened 15 liver cancer samples from this country for mutation at codon 249 of the p53 gene. Non-tumoral DNA from the patients showed a wild type genotype. Mutation at codon 249 of the p53 gene was detected in 10 of the 15 tumour tissues tested (67%). This frequency of mutation in codon 249 of the p53 gene is the highest described. These results confirmed that there is an association between countries of high aflatoxin intake and a high frequency of mutation in codon 249 of p53 gene, and that HBV alone does not contribute to these base changes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390289      PMCID: PMC1968506          DOI: 10.1038/bjc.1993.258

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  CircumVent thermal cycle sequencing and alternative manual and automated DNA sequencing protocols using the highly thermostable VentR (exo-) DNA polymerase.

Authors:  L E Sears; L S Moran; C Kissinger; T Creasey; H Perry-O'Keefe; M Roskey; E Sutherland; B E Slatko
Journal:  Biotechniques       Date:  1992-10       Impact factor: 1.993

2.  Cancer genes. Telling changes of base.

Authors:  A L Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

3.  Hepatocellular carcinoma mutation.

Authors:  N K Hayward; G J Walker; W Graham; E Cooksley
Journal:  Nature       Date:  1991-08-29       Impact factor: 49.962

4.  Epidemiology of primary hepatocellular carcinoma in Senegal.

Authors:  B Diop; F Denis; F Barin; J Perrin; J P Chiron; A Goudeau; P Coursaget; P Maupas
Journal:  Prog Med Virol       Date:  1981

5.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

6.  Use of 33P for Sanger DNA sequencing.

Authors:  R J Zagursky; P S Conway; M A Kashdan
Journal:  Biotechniques       Date:  1991-07       Impact factor: 1.993

Review 7.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

8.  Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas.

Authors:  Y Murakami; K Hayashi; S Hirohashi; T Sekiya
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

9.  [Hepatitis B and primary cancer of the liver in intertropical Africa].

Authors:  P Coursaget; B Yvonnet; J L Barres; J Perrin; E Tortey; B Diop; P Kocheleff; B Duflo; S M'Boup; I Diop-Mar
Journal:  Rev Epidemiol Sante Publique       Date:  1985       Impact factor: 1.019

10.  Low frequency of p53 gene mutation in tumors induced by aflatoxin B1 in nonhuman primates.

Authors:  Y Fujimoto; L L Hampton; L D Luo; P J Wirth; S S Thorgeirsson
Journal:  Cancer Res       Date:  1992-02-15       Impact factor: 12.701

View more
  17 in total

Review 1.  Non-viral causes of hepatocellular carcinoma.

Authors:  Wojciech Blonski; David S Kotlyar; Kimberly A Forde
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

2.  Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan.

Authors:  Yone-Han Mah; Ching-Sheng Hsu; Chen-Hua Liu; Chun-Jen Liu; Ming-Yang Lai; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-02-06       Impact factor: 6.047

3.  Aspergillus has distinct fatty acid synthases for primary and secondary metabolism.

Authors:  D W Brown; T H Adams; N P Keller
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

4.  Interaction of DNA repair gene polymorphisms and aflatoxin B1 in the risk of hepatocellular carcinoma.

Authors:  Jin-Guang Yao; Xiao-Ying Huang; Xi-Dai Long
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 5.  Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.

Authors:  Daniel Lin; Jennifer Wu
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

6.  Hepatocellular carcinoma and liver cirrhosis TP53 mutation analysis reflects a moderate dietary exposure to aflatoxins in Espírito Santo State, Brazil.

Authors:  Fernanda Magri de Carvalho; Thiago de Almeida Pereira; Patrícia Lofego Gonçalves; Robson Dettmann Jarske; Fausto Edmundo Lima Pereira; Iuri Drumond Louro
Journal:  Mol Biol Rep       Date:  2013-05-07       Impact factor: 2.316

Review 7.  Hepatocellular carcinoma p53 G > T transversions at codon 249: the fingerprint of aflatoxin exposure?

Authors:  T Lasky; L Magder
Journal:  Environ Health Perspect       Date:  1997-04       Impact factor: 9.031

8.  249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients.

Authors:  Jeronimo A Nogueira; Suzane K Ono-Nita; Marcelo E Nita; Marcelo M T de Souza; Eliane P do Carmo; Evandro S Mello; Cristovan Scapulatempo; Denise C Paranaguá-Vezozzo; Flair J Carrilho; Venancio A F Alves
Journal:  BMC Cancer       Date:  2009-06-26       Impact factor: 4.430

Review 9.  Current understanding on aflatoxin biosynthesis and future perspective in reducing aflatoxin contamination.

Authors:  Jiujiang Yu
Journal:  Toxins (Basel)       Date:  2012-10-25       Impact factor: 4.546

10.  A population-based study to investigate host genetic factors associated with hepatitis B infection and pathogenesis in the Chinese population.

Authors:  Zheng Zeng; Li Guan; Ping An; Shan Sun; Stephen J O'Brien; Cheryl A Winkler
Journal:  BMC Infect Dis       Date:  2008-01-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.